Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 924061 | ISIN: FR0004040608 | Ticker-Symbol: 9BA
Frankfurt
21.01.25
21:49 Uhr
4,985 Euro
+0,280
+5,95 %
1-Jahres-Chart
ABC ARBITRAGE SA Chart 1 Jahr
5-Tage-Chart
ABC ARBITRAGE SA 5-Tage-Chart
RealtimeGeldBriefZeit
4,9255,13021.01.
GlobeNewswire (Europe)
451 Leser
Artikel bewerten:
(2)

ABC arbitrage - Information Notice Regarding Paragraph 4.1 of the Consolidated Accounts Included in the 2023 Annual Financial Report

Finanznachrichten News

ABC arbitrage - Information Notice Regarding Paragraph 4.1 of the Consolidated Accounts Included in the 2023 Annual Financial Report

In accordance with Article 17 of the MAR regulation concerning the concept of insider information, and despite the gross financial impact for the first half of 2024 being estimated at only €230K, ABC arbitrage announces that Quartys Limited (100% owned subsidiary) received, on August 30, 2024, a letter from the Swiss Federal Tax Administration ("AFC") rejecting the refund of withholding taxes.

  • Recap of Events - As explained in our 2023 annual financial report (https://www.abc-arbitrage.com/financial-information/financial-reports/), page 60, paragraph 4.1, Quartys Limited is subject to a review regarding its requests for refund of the withholding tax ("RAS") addressed to the Swiss Federal Tax Administration ("AFC") for the years 2016 to 2019 and by extension until 2023. Given the risks concerning the recovery time of these RAS and the recent rise in interest rates, the Group, in accordance with IFRS 13, decided to update the receivable as of December 31, resulting in a negative impact on the 2023 financial year results amounting to €1.35M (directly included in the line "Net gains on financial instruments at fair value through profit or loss" - see also the 2023 Results Presentation (March 2024), pages 13 and 14).

  • AFC Letter - The AFC formally transmitted its decision to Quartys Limited via a letter received on August 30, 2024. While the AFC formally recognizes that Quartys Limited is indeed the legal owner of the shares for which the refund of the withholding tax was requested, it refuses to grant the refund for a total of 7.4 million CHF (approximately €7.9 million at the current CHF/EUR exchange rate), amounts slightly lower than those reported during the publication of the 2023 accounts.

  • Next Steps - The Group confirms that it acted in compliance with the rules of the relevant tax authorities. Upon receiving the letter from the AFC, the Group confirms the legitimacy of the refund request submitted by Quartys Limited and remains confident in the outcome of this dispute. To support this position with an external opinion, as was done on this matter during the publication of the 2023 accounts, the Group consulted a renowned Swiss tax law firm, which confirmed that this letter does not change its analysis and that the chances of success are more likely than not, in accordance with the terminology required by international standards (IFRIC 23).

As explained in the 2023 financial report, the entire appeal process could take several years. For this reason, the receivable was discounted over a five-year period in the 2023 accounts, resulting in a negative impact of €1.35M for that year. The Group has planned to update these amounts for the publication of the first half of 2024 accounts, adding an additional negative impact of €0.23M to that of the 2023 financial year, for a total of €1.58M in impairments of the receivable in the Group's accounts.

The various press releases can be viewed on the company's website at the following link abc-arbitrage, in the Shareholderssection, under Publications.

The next communication is scheduled for September 24 at 7:00 AM for the announcement of the first-half 2024 results.

Contacts: abc-arbitrage.com
Relations actionnaires: actionnaires@abc-arbitrage.com
Relations presse: VERBATEE / v.sabineu@verbatee.comEURONEXT Paris - Compartiment B
ISIN: FR0004040608
Reuters BITI.PA / Bloomberg ABCA FP

Attachment

  • 2024 ABCA Communique´ d'information VEng (https://ml-eu.globenewswire.com/Resource/Download/d7ab4bd4-d024-4748-8c02-b203a60a8e25)

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Diesen Artikel auf Deutsch lesen
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.